Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Hot off the press!
Thrilled to share my editorial ‘All roads lead to ROME: convergence of evidence in precision oncology’ in ESMO journal ESMO Open on the landmark ROME trial published in Nature Portfolio journal Nature Medicine.
ROME is a milestone for precision medicine and tumoragnostic precision oncology.
Huge congratulations to the brilliant ROME investigators!.”
Read the Full Editorial on ESMO Open
Title: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Authors: Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, Sara Lonardi, Simone Scagnoli, Lorenzo Fornaro, Valentina Guarneri, Ugo De Giorgi, Paolo Antonio Ascierto, Giovanni Blandino, Giulia D’Amati, Massimo Aglietta, Chiara Cremolini, Pierfranco Conte, Edoardo Crimini, Maurizio Ceracchi, Simona Pisegna, Sofia Verkhovskaia, Roberto Bordonaro, Sergio Bracarda, Giovanni Butturini, Lucia Del Mastro, Andrea DeCensi, Agnese Fabbri, Elisabetta Fenocchio, Stefania Gori, Giulio Metro, Annamaria Pessino, Daniele Pozzessere, Fabio Puglisi, Stefano Tamberi, Alberto Zambelli, Donatella Marino, Ettore Capoluongo, Federico Cappuzzo, Bruna Cerbelli, Giuseppe Giannini, Umberto Malapelle, Federica Mazzuca, Marianna Nuti, Giancarlo Pruneri, Maurizio Simmaco, Lidia Strigari, Giuseppe Tonini, Nello Martini, Andrea Botticelli
Read the Full Article on Nature Medicine
More posts featuring Vivek Subbiah.